Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CVAC

CureVac N.V.

Apr 25 • 01:03PM ET

2.27

Dollar change -0.24
Percentage change -9.56	%

Healthcare • Biotechnology • Germany • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IBB IDNA ONEQ GINN GERM VT BIB BBC BBP ESGV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.53	Insider Own	59.08%	Shs Outstand	223.88M	Perf Week	-6.97%
Market Cap	508.21M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.00%	Shs Float	91.60M	Perf Month	-22.79%
Income	-319.30M	PEG	-	EPS next Q	-0.26	Inst Own	10.02%	Short Float	4.57%	Perf Quarter	-38.15%
Sales	45.75M	P/S	11.11	EPS this Y	29.68%	Inst Trans	-2.61%	Short Ratio	5.30	Perf Half Y	-60.11%
Book/sh	2.85	P/B	0.80	EPS next Y	37.69%	ROA	-35.79%	Short Interest	4.19M	Perf Year	-68.69%
Cash/sh	2.19	P/C	1.03	EPS next 5Y	-10.76%	ROE	-51.09%	52W Range	2.34 - 12.36	Perf YTD	-46.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-47.21%	52W High	-81.63%	Beta	2.51
Dividend TTM	-	Quick Ratio	3.41	Sales past 5Y	-	Gross Margin	-288.52%	52W Low	-2.99%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	3.56	EPS Y/Y TTM	-124.27%	Oper. Margin	-722.38%	RSI (14)	26.14	Volatility	6.29% 6.32%
Employees	1100	Debt/Eq	0.07	Sales Y/Y TTM	-57.32%	Profit Margin	-697.90%	Recom	2.50	Target Price	8.51
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	6.41%	Payout	-	Rel Volume	1.76	Prev Close	2.51
Sales Surprise	-27.23%	EPS Surprise	-43.37%	Sales Q/Q	58.86%	Earnings	Apr 24 BMO	Avg Volume	789.46K	Price	2.27
SMA20	-19.12%	SMA50	-27.08%	SMA200	-59.13%	Trades		Volume	792,575	Change	-9.56%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	Leerink Partners	Outperform → Market Perform	$12 → $4
Jun-08-23	Initiated	SVB Securities	Outperform	$13
Jan-19-23	Upgrade	UBS	Neutral → Buy	$8 → $18
Jan-09-23	Upgrade	Jefferies	Hold → Buy	$9 → $21
Jan-21-22	Downgrade	BofA Securities	Neutral → Underperform	$55 → $20
Jan-18-22	Initiated	JMP Securities	Mkt Outperform	$52
Oct-22-21	Initiated	Deutsche Bank	Hold	$35
Jun-17-21	Downgrade	BofA Securities	Buy → Neutral	$50
Apr-26-21	Resumed	Credit Suisse	Underperform
Apr-26-21	Initiated	Guggenheim	Neutral
Dec-10-20	Downgrade	Credit Suisse	Neutral → Underperform	$50 → $47
Sep-08-20	Initiated	Jefferies	Hold	$58
Sep-08-20	Initiated	Credit Suisse	Neutral	$68
Sep-08-20	Initiated	BofA Securities	Buy	$70

Show Previous Ratings

Today 05:10AM	Analyst Report: CureVac N.V. (Morningstar Research) -9.56%
Apr-24-24 12:27PM	CureVac Begins Early Stage Portion of Investigational Vaccine Trial (MT Newswires)
07:30AM	CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update (ACCESSWIRE)
07:20AM	CureVac Appoints Thaminda Ramanayake as New Chief Business Officer (ACCESSWIRE)
07:20AM	CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK (ACCESSWIRE)
06:22AM	Loading…
06:22AM	CureVac to cut costs in restructuring (BioPharma Dive)
Apr-18-24 07:15AM	CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 (ACCESSWIRE) -5.06%
Apr-16-24 07:15AM	CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines (ACCESSWIRE)
Apr-04-24 09:10AM	CureVac, chasing Moderna's mRNA flu vaccine, runs into the same B strain problems (FierceBiotech.com)
07:15AM	CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK (ACCESSWIRE)
Feb-22-24 06:55PM	Analyst Report: CureVac N.V. (Morningstar Research)
Jan-26-24 09:35AM	Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC) (Zacks)
Jan-25-24 09:35AM	Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC) (Zacks)
Jan-05-24 10:47AM	CureVac touts COVID-19 vax data as platform validation, despite grade 3 adverse events (FierceBiotech.com)
07:30AM	CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform (ACCESSWIRE)
08:49AM	Loading…
Dec-30-23 08:49AM	13 Best Get Rich Quick Stocks To Buy (Insider Monkey)
Dec-19-23 10:15PM	Analyst Report: CureVac N.V. (Morningstar Research) -29.55%
01:43PM	Rebel's Edge - December 19: $RUN, $AFRM, $CVAC, and College Football Recruits (TheStreet.com)
12:31PM	Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today? (Benzinga)
09:35AM	CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE (ACCESSWIRE)
09:12AM	UPDATE 2-German court quashes CureVac patent after challenge by BioNTech (Reuters)
08:35AM	German court quashes CureVac patent after challenge by BioNTech (Reuters)
Nov-21-23 09:55AM	Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-20-23 03:41PM	Analyst Report: CureVac N.V. (Morningstar Research)
Nov-15-23 01:58PM	CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:03AM	Q3 2023 CureVac NV Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:30AM	CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update (ACCESSWIRE)
Nov-01-23 08:15AM	CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK (ACCESSWIRE)
Oct-31-23 07:12PM	12 Best German Stocks To Buy Now (Insider Monkey)
Sep-29-23 09:07AM	Why CureVac Stock Plunged Today (Motley Fool) +5.08%
11:27AM	Loading…
Sep-28-23 11:27AM	UPDATE 1-German court suspends mRNA patent trial against BioNTech (Reuters) -8.58%
07:15AM	CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany (ACCESSWIRE)
04:16AM	CORRECTED-German court suspends mRNA patent trial against BioNTech (Reuters)
Sep-27-23 06:44PM	Analyst Report: CureVac N.V. (Morningstar Research)
Sep-12-23 07:15AM	CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage (ACCESSWIRE)
Aug-17-23 07:15AM	CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update (ACCESSWIRE) -8.08%
Aug-08-23 06:26AM	Further weakness as CureVac (NASDAQ:CVAC) drops 9.7% this week, taking one-year losses to 40% (Simply Wall St.)
Aug-01-23 07:15AM	CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK (ACCESSWIRE)
Jul-20-23 06:01AM	The Petri Dish: CureVac's top scientist steps down; Novo Nordisk inks another Boston collab (American City Business Journals)
Jul-14-23 07:15AM	CureVac Announces Update to the Management Team (ACCESSWIRE)
Jul-13-23 07:15AM	CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights (ACCESSWIRE)
Jun-28-23 02:40PM	Are Investors Undervaluing CureVac N.V. (NASDAQ:CVAC) By 45%? (Simply Wall St.)
Jun-23-23 12:35PM	Why Shares of CureVac Jumped This Week (Motley Fool) +7.17%
Jun-20-23 06:29PM	Why CureVac Stock Leaped 12% Higher Today (Motley Fool) +12.01%
07:25AM	CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma (ACCESSWIRE)
07:10AM	CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board (ACCESSWIRE)
Jun-19-23 01:33PM	CureVac Announces Voting Results of General Meeting (ACCESSWIRE)
Jun-01-23 02:15PM	CureVac First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -5.60%
12:39PM	Analyst Report: CureVac N.V. (Morningstar Research)
May-30-23 07:30AM	CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update (ACCESSWIRE)
May-24-23 06:07AM	CureVac N.V.'s (NASDAQ:CVAC) market cap surged US$362m last week, private equity firms who have a lot riding on the company were rewarded (Simply Wall St.) -6.12%
May-19-23 08:26AM	CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology (Reuters)
08:19AM	UPDATE 1-CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology (Reuters)
07:15AM	CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech (ACCESSWIRE)
May-08-23 07:15AM	CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK (ACCESSWIRE)
May-02-23 12:11AM	CureVac N.V. (NASDAQ:CVAC) Q4 2022 Earnings Call Transcript (Insider Monkey)
May-01-23 05:37PM	Analyst Report: CureVac N.V. (Morningstar Research) -5.02%
06:06AM	Analyst Forecasts Just Became More Bearish On CureVac N.V. (NASDAQ:CVAC) (Simply Wall St.)
Apr-26-23 01:14AM	Q4 2022 CureVac NV Earnings Call (Thomson Reuters StreetEvents)
Apr-18-23 07:30AM	CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023 (ACCESSWIRE)
Apr-17-23 03:33PM	CureVac N.V.'s (NASDAQ:CVAC) Shares May Have Run Too Fast Too Soon (Simply Wall St.)
Mar-28-23 04:25PM	CureVac Announces Voting Results of Extraordinary General Meeting (ACCESSWIRE)
02:50PM	Analyst Report: CureVac N.V. (Morningstar Research)
Mar-23-23 09:45AM	As CureVac N.V.'s market cap (NASDAQ:CVAC) drops to US$1.4b, insiders might be questioning their decision to buy earlier this year (Simply Wall St.)
Mar-09-23 07:17PM	Analyst Report: CureVac N.V. (Morningstar Research) -7.92%
Feb-23-23 08:39AM	The past year for CureVac (NASDAQ:CVAC) investors has not been profitable (Simply Wall St.)
Feb-10-23 04:20PM	CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares (ACCESSWIRE)
Feb-07-23 02:20AM	CureVac Announces Proposed Public Offering of Common Shares (ACCESSWIRE) -11.34%
Feb-01-23 07:15AM	CureVac Welcomes Myriam Mendila as New Chief Development Officer (ACCESSWIRE) +9.78%
Jan-31-23 09:35AM	CureVac Named as One of the Worlds Most Dynamic Innovators by LexisNexis(R) (ACCESSWIRE) -7.25%
Jan-30-23 10:17AM	CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs (Benzinga)
08:30AM	CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (ACCESSWIRE)
Jan-20-23 10:24AM	Omicron subvariant gains more ground in U.S. to account for 49.1% of new COVID cases, CDC data show (MarketWatch)
Jan-19-23 03:21PM	CureVac Can Finally Compete With Moderna. Its an Under-the-Radar mRNA Story. (Barrons.com) +9.18%
01:56PM	UBS: CureVac has a potentially competitive mRNA platform (MarketWatch)
Jan-18-23 03:44PM	7 Biotech Stocks That Will Make You Rich in 10 Years (InvestorPlace)
Jan-12-23 05:39AM	The Petri Dish: Moderna looks at new price tag for Covid vaccine (American City Business Journals) -14.40%
Jan-11-23 12:16PM	BioNTech seeks to have CureVac patent nullified in German court (Reuters)
Jan-10-23 04:16PM	Why CureVac's Shares Jumped on Tuesday (Motley Fool) +20.56%
02:21PM	CureVac Stock Has Nearly Doubled in 3 Days (Barrons.com)
Jan-09-23 10:39AM	Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of governments pandemic response (MarketWatch) +25.42%
10:27AM	Covid vaccine makers CureVac and Novavax appoint new chiefs (Financial Times)
07:15AM	CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 (ACCESSWIRE)
05:21AM	CureVac shares surge after preliminary data on COVID-19 and flu shots (MarketWatch)
Jan-07-23 07:03AM	CureVac N.V. (NASDAQ:CVAC) Shares Could Be 46% Below Their Intrinsic Value Estimate (Simply Wall St.)
Jan-06-23 06:54PM	Analyst Report: CureVac N.V. (Morningstar Research) +29.47%
07:15AM	CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs (ACCESSWIRE)
Dec-27-22 09:01AM	CureVac N.V. (NASDAQ:CVAC) Q3 2022 Earnings Call Transcript (Insider Monkey) -8.59%
Dec-14-22 04:25PM	CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program (ACCESSWIRE) -11.26%
Nov-24-22 06:18AM	Private equity firms are CureVac N.V.'s (NASDAQ:CVAC) biggest owners and were hit after market cap dropped US$101m (Simply Wall St.)
Nov-22-22 09:55AM	Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade (Zacks)
Nov-16-22 09:00AM	Edited Transcript of CVAC.OQ earnings conference call or presentation 16-Nov-22 2:00pm GMT (Thomson Reuters StreetEvents)
Nov-11-22 07:20AM	CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102 (ACCESSWIRE)
Nov-10-22 07:15AM	CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022 (ACCESSWIRE) +5.14%
Oct-14-22 08:37AM	Having purchased 97m worth of CureVac N.V. (NASDAQ:CVAC) stock, the recent 4.6% pullback is not what insiders may have expected (Simply Wall St.)
Sep-28-22 09:31AM	Bet on These 4 Biotech Stocks With Bright Prospects (Zacks)
Sep-16-22 09:34AM	The past year for CureVac (NASDAQ:CVAC) investors has not been profitable (Simply Wall St.)
Sep-02-22 10:05AM	UPDATE 1-Pfizer, BioNTech seek to revoke CureVac's patent infringement claims (Reuters)
09:37AM	Pfizer, BioNTech seek to revoke CureVac's patent infringement claims (Reuters)
Aug-29-22 09:35AM	Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks (Zacks)

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mulbe in 2000 and is headquartered in Tubingen, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVAC

CureVac N.V.

Upgrade your FINVIZ experience